Text Size
23 studies found for:    Cobicistat[TREATMENT] AND HIV [CONDITION]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide;   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
2 Recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide;   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
3 Active, not recruiting Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/GS-7340;   Drug: elvitegravir/cobicistat/emtricitabine/ tenofovir df
4 Active, not recruiting Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: darunavir/cobicistat/emtricitabine/GS-7340;   Drug: darunavir + cobicistat + emtricitabine/tenofovir df
5 Active, not recruiting Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF;   Drug: cobicistat and atazanavir or cobicistat and darunavir
6 Recruiting Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Cobicistat;   Drug: Darunavir
7 Recruiting Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Conditions: HIV;   HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
8 Recruiting Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
9 Not yet recruiting Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide;   Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or GS-9350 + atazanavir + FTC/TDF
10 Recruiting Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
11 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: NNRTI plus FTC/TDF
12 Active, not recruiting Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
13 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir-boosted protease inhibitor plus Truvada
14 Not yet recruiting Bioequivalence (BE) Study of Individual Atazanavir and Cobicistat Compared to Atazanavir in Fixed Dose Combination With Cobicistat
Condition: Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions: Drug: Atazanavir;   Drug: Cobicistat
15 Active, not recruiting Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: GS-9350 + atazanavir + emtricitabine/tenofovir DF;   Drug: Comparator: ritonavir + atazanavir + emtricitabine/tenofovir DF
16 Active, not recruiting Safety and Efficacy of GS-9350-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: 150 mg tablet GS- 9350;   Drug: ritonavir 100 mg capsule;   Drug: atazanavir 300 mg capsule;   Drug: emtricitabine/tenofovir DF 200/300 mg tablet;   Drug: ritonavir placebo;   Drug: GS-9350 placebo
17 Recruiting Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Conditions: Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Intervention: Drug: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF)
18 Recruiting Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
Condition: HIV
Intervention: Drug: (FDC) ELV/COBI/FTC/TDF
19 Not yet recruiting HIV Non-Occupational Post-Exposure Prophylaxis
Condition: Human Immunodeficiency Virus
Intervention: Drug: Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
20 Completed A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions
Condition: Healthy Participants
Interventions: Drug: darunavir;   Drug: cobicistat
To Top

Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results
† Indicates status has not been verified in more than two years